Chang-xin Li

Dr. Chang-xin Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2023 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
SXSui-Yi Xu
Sui-Yi Xu
QZQi Zhang
Qi Zhang
CLChang-xin Li
Chang-xin Li
Paroxysmal sympathetic hyperactivity (PSH) mainly occurs after acquired brain injury (ABI) and often presents with high fever, hypertension, tachycardia, tachypnea, sweating, and dystonia (increased muscle tone or spasticity). The pathophysiological mechanisms of PSH are not fully understood. Currently, there are several views: (1) disconnection theory, (2) excitatory/inhibitory ratio, (3) neuroendocrine function, and (4) neutrophil extracellular traps. Early diagnosis of PSH remains difficult, given the low specificity of its diagnostic tools and unclear pathogenesis. According to updated case analyses in recent years, PSH is now more commonly observed in patients with stroke, with tachycardia and hypertension as the main clinical manifestations, which is not fully consistent with previous data. To date, the PSH Assessment Measure tool is optimal for the early identification of PSH and stratification of symptom severity. Clinical strategies for the management of PSH are divided into three main points: (1) reduction of stimulation, (2) reduction of sympathetic excitatory afferents, and (3) inhibition of the effects of sympathetic hyperactivity on target organs. However, use of drugs and standards have not yet been harmonized. Further investigation on the relationship between PSH severity and long-term neurological prognosis in patients with ABI is required. This review aimed to determine the diagnostic and management challenges encountered in PSH after ABI.

24 January 2020 in Medical Science Monitor
Verified
Journal Article
Closed access
SXSui-Yi Xu
Sui-Yi Xu
ZLZe-Xing Li
Ze-Xing Li
XWXiao-Wei Wu
Xiao-Wei Wu
LLLing Li
Ling Li
CLChang-xin Li
Chang-xin Li
Todd's paralysis, a neurological abnormality characterized by temporary limb weakness or hemiplegia, typically occurs following a seizure, without enduring consequences. Since limb weakness or hemiplegia can also be a common symptom of an acute ischemic stroke, it is often difficult to diagnose Todd's paralysis in individuals experiencing an acute ischemic stroke if they do not have a pre-existing history of epilepsy. Given that there is a limited understanding of Todd's paralysis, this review discusses the history, prevalence, clinical manifestations, duration, etiology, and diagnosis of Todd's paralysis. A few factors that may help clinicians distinguish Todd's paralysis from other clinical indications are as follows: (1) Todd's paralysis is commonly observed after partial seizures or generalized tonic-clonic seizures. (2) The incidence of Todd's paralysis is greater if the epilepsy is associated with old age or stroke history. (3) The duration of Todd's paralysis can range from minutes to days, depending on the type of seizure or whether the patient has experienced cortical structural damage. (4) The etiology of Todd's paralysis is associated with cerebral perfusion abnormality after seizures. Further research is needed to explore factors that distinguish Todd's paralysis from other indications that may lead to limb weakness in order to improve the diagnosis of Todd's paralysis.

7 December 2021 in Medical Science Monitor
Verified
Journal Article
Open access
SXSui-Yi Xu
Sui-Yi Xu
MSMao-Mei Song
Mao-Mei Song
LLLing Li
Ling Li
CLChang-xin Li
Chang-xin Li
Adie’s Pupil: A Diagnostic Challenge for the Physician - Article abstract #934657

1 April 2021 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
SXSui-Yi Xu
Sui-Yi Xu
HLHui-Juan Li
Hui-Juan Li
JHJing Huang
Jing Huang
XLXiu-Ping Li
Xiu-Ping Li
CLChang-xin Li
Chang-xin Li
Migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraine, and women are more affected than men. The aura symptoms are diverse; however, when MBA is combined with DOC, the clinical manifestations are more complicated. Coma is the most common clinical manifestation. The overall duration of the patient’s DOC is short and can often return to normal within half an hour. Headache often occurs after regaining consciousness and can also occur at the same time as DOC. The most common headache is located at the occipital region. Although DOC is reversible, considering the current small number of cases, we still need to improve our understanding of the disease to avoid misdiagnosis. The MBA patient’s electroencephalogram and cerebral blood flow perfusion may have transient changes and may return to normal in the interictal period or after the DOC. Although triptans have traditionally been contraindicated in MBA under drug instructions, the evidence of basilar artery constriction, as postulated in MBA, is lacking. Lasmiditan is currently the first and only 5-HT 1F receptor agonist approved by the Food and Drug Administration. The calcitonin gene-related peptide receptor antagonists and monoclonal antibody therapies may be the most promising for future consideration. Here, the pathophysiology, clinical manifestations, diagnostic tools, and treatment progress for MBA with DOC are reviewed.

17 November 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
MSMao‐Mei Song
Mao‐Mei Song
TCTing‐Yan Chen
Ting‐Yan Chen
SSShi‐Na Song
Shi‐Na Song
YGYing‐Jie Gao
Ying‐Jie Gao
CLChang-xin Li
Chang-xin Li
SXSui-Yi Xu
Sui-Yi Xu
Aims: C‐X‐C motif chemokine ligand 10 (CXCL10) is a member of the CXC chemokine family, known as a classical pain‐related chemokine. While CXCL10 is implicated in neuropathic pain, its role in vestibular migraine (VM) remains unclear. Methods: Serum CXCL10 levels correlated with dizziness and headache severity in VM patients. In the rat VM model, CXCL10, C‐X‐C motif chemokine receptor 3 (CXCR3), and phosphatidylinositol 4,5‐bisphosphate 3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway expression were evaluated to explore the potential mechanisms of CXCL10 in VM. Results: Serum CXCL10 levels in VM patients were significantly elevated and positively correlated with headache and dizziness severity. In the rat VM model, CXCL10 and CXCR3 expression in the trigeminal nucleus caudalis and vestibular nuclei were significantly increased. Additionally, molecules related to the PI3K/AKT signaling pathway and downstream inflammatory factors showed significantly elevated expression. Conclusion: CXCL10 activates the PI3K/AKT signaling pathway, promoting the release of inflammatory factors, including interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α, and is thus involved in the pathogenesis of VM.

1 March 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SXSui-Yi Xu
Sui-Yi Xu
HLHui-Juan Li
Hui-Juan Li
SLShun Li
Shun Li
QRQian-Qian Ren
Qian-Qian Ren
JLJian-Lin Liang
Jian-Lin Liang
CLChang-xin Li
Chang-xin Li
High temperature requirement serine peptidase A1 (HTRA1) related cerebral small vessel disease (CSVD) includes both symptomatic heterozygous HTRA1 variant carrier and cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) patients. Presently, most reported symptomatic heterozygous HTRA1 variant carrier cases are sporadic family reports with a lack of specific characteristics. Additionally, the molecular mechanism of heterozygous HTRA1 gene variants is unclear. We conducted this review to collect symptomatic carriers of heterozygous HTRA1 gene variants reported as of 2022, analyzed all pathogenicity according to American College of Medical Genetics and Genomics (ACMG) variant classification, and summarized the cases with pathogenic and likely pathogenic HTRA1 variants gender characteristics, age of onset, geographical distribution, initial symptoms, clinical manifestations, imaging signs, HTRA1 gene variant information and to speculate its underlying pathogenic mechanisms. In this review, we summarized the following characteristics of pathogenic and likely pathogenic symptomatic HTRA1 variant carriers: to date, the majority of reported symptomatic HTRA1 carriers are in European and Asian countries, particularly in China which was found to have the highest number of reported cases. The age of first onset is mostly concentrated in the fourth and fifth decades. The heterozygous HTRA1 gene variants were mostly missense variants. The two variant sites, 166– 182 aa and 274– 302 aa, were the most concentrated. Clinicians need to pay attention to de novo data and functional data, which may affect the pathogenicity analysis. The decrease in HtrA1 protease activity is currently the most important explanation for the genetic pathogenesis.